Previous 10 | Next 10 |
Virtual event on Tuesday, May 3 rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuti...
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central n...
- 5 th Annual Neuroscience Innovation Forum - - BIO-Europe Spring ® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “...
Reviva Pharmaceuticals press release (NASDAQ:RVPH): FY GAAP EPS of -$0.58 beats by $0.05. As of December 31, 2021, the Company’s cash totaled approximately $29.7 million compared to approximately $8.8 million as of December 31, 2020. For further details see: Reviva Pharmaceutical...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDA...
Reviva Pharmaceuticals (NASDAQ:RVPH) announced that the first patients have been dosed in a pivotal Phase 3 study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia. Phase 3 RECO...
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reviva Pharma...
3 Penny Stocks to Watch in Mid-January 2022 With penny stocks and blue chips continuing to navigate the volatile waters of 2022, there is a lot for investors to understand. When it comes to penny stocks specifically, we see that speculation is extremely high. This means that knowing...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday! Source: Shutterstock Moving stocks this morning are clinical trial results, collaboration ...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...